Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3Phase 2/3 1

Status

Recruiting 2Unknown 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Nausea 5Vomiting 4Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Weight Loss 1Radiation Injuries 1Neoplasms, Germ Cell and Embryonal 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Breast Neoplasms 1Anorexia Nervosa with Significantly Low Body Weight 1Anorexia 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Olanzapine × Clear all
NCT05705492 2026-01-21

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

OHSU Knight Cancer Institute

Phase 2 Recruiting
66 enrolled
Gastrointestinal

Anorexia, Cachexia, Esophageal Neoplasms, Neoplasms, Colorectal Neoplasms, Weight Loss

NCT03118986 2025-10-08

RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

The Hospital for Sick Children

Phase 2 Recruiting
200 enrolled

Nausea, Neoplasms, Vomiting

NCT02400866 2015-03-27

A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy

Korean South West Oncology Group

Phase 2 Unknown
58 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡